Latest Information Update: 05 May 1998
At a glance
- Originator NPS Allelix
- Class Antimigraines
- Mechanism of Action Serotonin 1D receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 05 May 1998 Discontinued-Preclinical for Migraine in Canada (Unknown route)
- 13 Aug 1996 No-Development-Reported for Migraine in Canada (Unknown route)